The Australian medical device market is a complex and contentious issue, with a recent deal made by then-health minister Greg Hunt in 2022 locking 14 million privately insured Australians into paying some of the highest prices in the world for surgical hardware. This deal, endorsed by current health minister Mark Butler, has been criticized for benefiting industry over the Australian community. The Prescribed List, a price-setting schedule dictating what private health funds must pay hospitals for over 10,000 medical devices, is at the heart of this controversy. Prices for these devices are often far higher than those paid in public hospitals, leading to privately insured Australians paying up to three times more than overseas patients. This, in turn, pushes up insurance premiums and isolates manufacturers from normal commercial competition, forcing policyholders to subsidize corporate profits. The deal has been defended by Hunt, who argues that it put downward pressure on insurance premiums and was supported by Labor before the 2022 election. However, internal Department of Health documents show public servants formally refused to endorse the agreement, warning of financial risks and uncosted concessions. The latest figures from the Australian Prudential Regulation Authority show private health funds paid $2.52 billion for medical devices in the year to March 2026, a 3.2% increase on the previous year. The medical devices industry argues that the premiums charged by private health insurers are too high, and that when device companies drop their prices, insurers simply pocket the difference rather than dropping insurance premiums. The situation raises a deeper question about the balance between industry and community needs in healthcare policy, and the role of government in regulating prices and ensuring access to affordable medical technology.
